Our board

The Board of Directors is the company’s highest administrative body subordinate to the AGM. The work of Abliva’s Board of Directors is regulated by applicable laws and ordinances, and by the Board of Directors’ rules of procedure, which are adopted annually. The rules of procedure contain rules for dividing responsibilities between the Board of Directors and CEO, financial reporting and audit issues.

David Laskow-Pooley

Chairman (2017, elected 2016)

Born: 1954

Education: BSc Pharmacy (1st), Pharmaceutical/ Chemical engineering specialty and QP., Sunderland School of Pharmacy.

Other ongoing assignments: Director of the Board of Pharmafor Ltd. and LREsystem Ltd. Chairman of the Board of OSPT Ltd., UK. QP in HMR Ltd.

Previous assignments in the last five years: Director of the Board of Marker Therapeutics Inc., USA.

No. of shares in Abliva: 2,295,828.

Other: Non-affiliated to the Company, the management and to major owners.

David Bejker

Director (2017)

Born: 1975

Education: M.Sc. (Econ.), Stockholm School of Economics.

Other ongoing assignments: Director of the Board of Disruptive Pharma Holding AB and Amylonix AB, CEO and Director of the Board of Affibody AB, and CEO of Affibody Medical AB. Deputy Director of the Board of Abliva Incentive AB.

Previous assignments in the last five years: Director of the Board of LIDDS AB.

Holdings in Abliva: 269,055 shares and 1,500,000 warrants of series 2023/2027:4.

Other: Non-affiliated to the Company, the management and to major owners.

Roger Franklin

Director (2020)

Born: 1979

Education: M.Biochem (1st class), Molecular & Cellular Biochemistry, University of Oxford (UK), PhD, MRC Laboratory of Molecular Biology from University of Cambridge (UK).

Other ongoing assignments: Partner at Hadean Ventures. Director at Gesynta Pharma AB (Sweden), Crosslanes Holding AB (Sweden), TargED Biopharmaceuticals B.V. (Netherlands), and Complement Therapeutics GmbH (Germany). Deputy Director at HVentures AB (Sweden), HVentures Capital I AB (Sweden), and HVentures Capital II AB (Sweden). Board observer/guest at Step Pharma SAS (France) and Contineum Therapeutics Inc. (USA).

Previous assignments over the past five years: Deputy Director at Saga Diagnostics AB (Sweden), Board observer at Emergence Therapeutics AG (Germany) and Cardior Pharmaceuticals GmbH (Germany).

No. of shares in Abliva: 237,030,157 (owned by legal entities related to the director).

Other: Non-affiliated to the company and the management, but not to major owners.

Denise Goode

Director (2018)

Born: 1958

Education: Institute of Chartered Accountants in England and Wales Chartered Accountant. B.Sc. Zoology from The University of Manchester (UK).

Other ongoing assignments: Director of the Board and CEO of QED Life Sciences Limited, Director of the Board at Alligator Bioscience, and VP Business Development at AnaMar AB.

Previous assignments in the last five years: Director of the Board of Dechra Pharmaceuticals PLC.

Holdings in Abliva: 1,500,000 warrants of series 2023/2027:4.

Other: Non-affiliated to the company, the management, and to major owners.

Jan Törnell

Director (2017)

Born: 1960

Education: MD and PhD in physiology, University of Gothenburg.

Other ongoing assignments: CEO and Director of the Board of Innoext AB. Chairman of the Board of Glactone Pharma AB.

Previous assignments over the past five years: Chairman of the Board of LIDDS AB and Isofol Medical AB. Director of the Board of Hammars Bryggförening, Diaprost AB and Stayble Therapeutics AB. Deputy Director of the Board of LIDDS Pharma AB. Partner in P.U.L.S. AB.

Holdings in Abliva: 62,492 shares and 1,500,000 warrants of series 2023/2027:4.

Other: Non-affiliated to the Company, the management and to major owners.